©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Sep 27, 2021; 13(9): 1143-1153
Published online Sep 27, 2021. doi: 10.4254/wjh.v13.i9.1143
Published online Sep 27, 2021. doi: 10.4254/wjh.v13.i9.1143
Drug-induced liver injury and COVID-19: A review for clinical practice
Gabriela Xavier Ortiz, Matheus William Becker, Karin Hepp Schwambach, Graduate Program in Medicine Hepatology, Federal University of Health Sciences of Porto Alegre, Porto Alegre 90050-170, Rio Grande do Sul, Brazil
Gabriele Lenhart, Multiprofessional Residency Integrated in Health, Federal University of Health Sciences of Porto Alegre, Porto Alegre 90050-170, Rio Grande do Sul, Brazil
Cristiane Valle Tovo, Internal Medicine Department, Graduate Program in Medicine-Hepatology, Federal University of Health Sciences of Porto Alegre, Porto Alegre 90050-170, Rio Grande do Sul, Brazil
Carine Raquel Blatt, Pharmacoscience Department, Graduate Program in Medicine-Hepatology, Federal University of Health Sciences of Porto Alegre, Porto Alegre 90050-170, Rio Grande do Sul, Brazil
Author contributions: Ortiz GX, Lenhart G, Becker MW and Schwambach KH collected the data and wrote the paper; Blatt CR wrote and revised the paper; Tovo CV performed the final review of the manuscript with significant contributions; all authors approved the final version of the manuscript.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Corresponding author: Matheus William Becker, MSc, Pharmacist, Research Scientist, Graduate Program in Medicine Hepatology, Federal University of Health Sciences of Porto Alegre, Sarmento Leite, 245 Street, Porto Alegre 90050-170, Rio Grande do Sul, Brazil. matheuswbecker@gmail.com
Received: May 8, 2021
Peer-review started: May 8, 2021
First decision: May 13, 2021
Revised: May 18, 2021
Accepted: August 18, 2021
Article in press: August 18, 2021
Published online: September 27, 2021
Processing time: 136 Days and 19.4 Hours
Peer-review started: May 8, 2021
First decision: May 13, 2021
Revised: May 18, 2021
Accepted: August 18, 2021
Article in press: August 18, 2021
Published online: September 27, 2021
Processing time: 136 Days and 19.4 Hours
Core Tip
Core Tip: Coronavirus disease 2019 (COVID-19) is a multisystemic disease, and liver manifestations are an important aspect to be considered. One should pay attention to drug-induced liver injury, especially considering the off-label use of drugs in prophylactic and therapeutic regimens applied on large scales. A review of liver damage in patients with COVID-19 returned three studies involving remdesivir, tocilizumab, and a pharmacovigilance study. Liver disorders in COVID-19 patients and the use of several concomitant off-label drugs - potentially causing further liver damage - should be a warning sign for rapid identification and early intervention, thus preventing severe impairment in patients.